| Literature DB >> 20003977 |
Helen Williams1, Richard J Pease, Laura M Newell, Paul A Cordell, Robert M Graham, Mark T Kearney, Christopher L Jackson, Peter J Grant.
Abstract
BACKGROUND: Transglutaminase 2 (TG2), a cross-linking enzyme that confers supra-molecular structures with extra rigidity and resistance against proteolytic degradation, is expressed in the shoulder regions of human atherosclerotic plaques. It has been proposed that TG2 prevents tearing and promotes plaque repair at these potential weak points, and also promotes ectopic calcification of arteries. TG2 is also expressed within plaques that develop within the brachiocephalic arteries of apolipoprotein E (apoE) deficient mice.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20003977 PMCID: PMC2874840 DOI: 10.1016/j.atherosclerosis.2009.11.014
Source DB: PubMed Journal: Atherosclerosis ISSN: 0021-9150 Impact factor: 5.162
Proximal brachiocephalic artery morphometry.
| Gender | Genotype | Vessel area (×103 μm2) | Media area (×103 μm2) | Plaque area (×103 μm2) | Lumen area (×103 μm2) | Cap thickness (μm) | Plaque lipid (%) | Buried fibrous caps |
|---|---|---|---|---|---|---|---|---|
| Male ( | ApoE−/−TG2+/+ | 331.7 ± 20.3 | 83.5 ± 4.7 | 156.9 ± 19.0 | 141.4 ± 12.4 | 2.80 ± 0.26a | 35.7 ± 1.7 | 2.35 ± 0.33 |
| Female ( | ApoE−/−TG2+/+ | 317.8 ± 15.9 | 77.3 ± 4.4 | 165.1 ± 15.2 | 122.9 ± 7.5 | 3.62 ± 0.29 | 39.8 ± 1.7 | 1.74 ± 0.23 |
| Both ( | ApoE−/−TG2+/+ | 323.3 ± 12.4 | 79.7 ± 3.3 | 161.9 ± 11.8 | 130.2 ± 6.7 | 3.30 ± 0.21 | 38.1 ± 1.3b | 1.98 ± 0.20 |
| Male ( | ApoE−/−TG2−/− | 335.7 ± 8.8 | 82.5 ± 3.1 | 154.9 ± 7.6 | 143.7 ± 5.2 | 4.12 ± 0.45a | 34.3 ± 1.5 | 2.14 ± 0.22 |
| Female ( | ApoE−/−TG2−/− | 298.9 ± 12.6 | 82.0 ± 3.7 | 140.8 ± 11.6 | 122.3 ± 7.7 | 3.90 ± 0.33 | 34.3 ± 1.7 | 1.51 ± 0.25 |
| Both ( | ApoE−/−TG2−/− | 318.7 ± 7.8 | 81.9 ± 2.4 | 148.9 ± 6.7 | 132.7 ± 4.6 | 4.02 ± 0.29 | 34.4 ± 1.1b | 1.88 ± 0.17 |
Groups with the same superscript letter are significantly different from each other (p < 0.05).
Fig. 1Mouse proximal brachiocephalic artery plaques. Scale bar represents 25 μm in Panels B, D, F and H. Panel (A): TG2 wild-type mouse stained for TG2. TG2 antigen is present on the apparently normal endothelium and on various cells within the shoulder region and in the necrotic core, but is not present on the cap surface. Panel (B): Higher power detail of view of part of Panel A. Panel (C): Negative control, TG2 wild-type mouse processed without the primary antibody. Panel (D): Higher power detail of view of part of Panel C. Panel (E): TG2 knockout mouse stained for TG2 antigen. Panel (F): Higher power detail of view of part of Panel E. Panel (G): TG2 wild-type mouse stained for α-smooth muscle actin. Panel (H): Higher power detail of view of part of Panel G.
Fig. 2Sections of mouse brachiocephalic plaques stained for elastin. Scale bars represent 200 μm in Panel A and 100 μm in Panel B. Panel (A): Multiple buried caps (arrowheads) present in a plaque from an apoE/TG2 double-knockout mouse. Panel (B): A current rupture in a plaque from an apoE/TG2 double-knockout mouse (arrowhead). Red blood cells have permeated the plaque at the point of rupture.
Fig. 3Sections of human carotid and mouse brachiocephalic arteries stained for calcium. Scale bars represent 500 μm in Panel A, 100 μm in Panels B and C, 50 μm in Panels D and E. Panel (A): Crystalline calcium deposits in a longitudinal section of a human carotid arterial plaque. Panel (B): Higher power view of part of Panel A. Panel (C): Extensive calcification of both the plaque and arterial wall in a lesion from the brachiocephalic artery of an apoE/TG2 double-knockout mouse. Panel (D): Higher power view of a region of the lesion shown in Panel C. Panel (E): Low to moderate calcification in the brachiocephalic artery of an apoE single knockout mouse.